Review Article

Multiantibody Strategies for HIV

Andrew Hiatt, Larry Zeitlin, and Kevin J. Whaley

Mapp Biopharmaceutical Inc., 6160 Lusk Boulevard, C104, San Diego, CA 92121, USA

Correspondence should be addressed to Andrew Hiatt; andy.hiatt@mappbio.com

Received 15 March 2013; Revised 13 May 2013; Accepted 14 May 2013

Academic Editor: Roberto Burioni

Copyright © 2013 Andrew Hiatt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vaccination strategies depend entirely on the appropriate responsiveness of our immune system against particular antigens. For this active immunization to be truly effective, neutralizing antibodies (nAbs) need to efficiently counter the infectivity or propagation of the pathogen. Some viruses, including HIV, are able to take advantage of this immune response in order to evade nAbs. This review focuses on viral immune evasion strategies that result directly from a robust immune response to infection or vaccination. A rationale for multi-Ab therapy to circumvent this phenomenon is discussed. Progress in the formulation, production, and regulatory approval of monoclonal antibodies (mAbs) is presented.

1. Introduction

The persistence of HIV as a global epidemic has revealed our limited understanding of how immune barriers function to protect humans against disease [1]. Soon after the recognition of the HIV virus as the causative agent of AIDS, the prediction was made that a vaccine would be available for testing within two years [2]. In the intervening 30 years, the inability to create an effective protective or therapeutic vaccine can be attributed to a number of characteristics of HIV. Some of these characteristics naturally result in evasion from immune surveillance and are also utilized by other viruses [3–5]. Viral evasion in general can involve accumulation of point mutations on immune-dominant regions of surface proteins, glycosylation of functionally pivotal residues (the glycan shield) or their association with host serum components (e.g., lipoproteins) in order to mask them from the immune system, and cell-to-cell transmission. In addition, molecular mimicry, whereby the expression of proteins structurally similar to host defense proteins, can lead to viral persistence [6–9]. These strategies can in turn result in further damaging effects. The secondary consequences of molecular mimicry range from viral-induced autoimmune disease to chronic immune stimulation, for example, HCV-induced cryoglobulinemia.

In the particular case of HIV, immune evasion results from a variety of additional strategies. The incredible sequence diversity within each HIV subtype as well as within individuals during the course of active infection represents an enormous challenge to the immune system. Furthermore, HIV attacks the very cells that are needed to mount an effective and coordinated immune response. The destruction of CD4+ T cells can further facilitate viral replication [10]. Additional evasion strategies involve downregulation of MHC molecules [11–13], establishment of latent viral genomes that can result in production of infectious virus perhaps years later [14], as well as very high mutation rates of the viral genome resulting in infectious viruses that the immune response does not recognize [1, 15].

Evasion strategies that result directly from a robust immune response include neutralization interference by nonneutralizing antibodies (non-nAbs) [3], a potential for enhancement of viral infectivity due to the presence of anti-viral Abs [16], and the propensity of our memory immune system to become overly influenced by the earliest immune response after infection or vaccination. The uncertainties in the development of robust active immunization strategies for viruses such as HIV provide the rationale for passive immunization strategies that employ multiple mAbs as a basis for both protective and therapeutic clinical modalities against a variety of viral infections.

2. Interfering Nonneutralizing Abs (Non-nAbs)

The problem of non-nAb interference has been investigated in a number of viruses and represents a viral evasion strategy
that needs to be addressed if the development of new vaccines is to be successful. This type of evasion strategy also suggests that passive immunization may be an alternative. In the case of HCV, broadly crossneutralizing Abs (bnAbs) are most effective when directed against highly conserved and functionally critical epitopes (e.g., the CD81-binding site) among different genotypes [17–27]. However the binding of these HCV bnAbs may be inhibited by the presence of non-nAbs that bind proximal to the critical residues [28–34]. This hypothesis is still controversial [26] but recent experiments support the existence of interfering Ab populations [35].

In the case of influenza, humoral immunity resulting in the inactivation of the receptor-binding site on HA appears to be the main mechanism of influenza neutralization [36–39]. In addition, bnAbs often inhibit the fusion of the viral envelope with the endocytic vesicle membrane [20, 40–44]. Non-nAbs, if produced in sufficient abundance, may provide a basis for viral escape from the bnAbs [45–48]. Overall, the experimental results suggest that non-nAbs that bind to epitopes of HA may interfere with the binding of bnAbs to proximal neutralization epitopes.

Further evidence that prevalent non-nAbs can result in viral escape is found in severe acute respiratory syndrome coronavirus (SARS-CoV). Vaccine strategies, directed to preventing infection, have used the SARS-S viral glycoprotein as a target [49]. This strategy has proven to be problematic since vaccination for coronavirus may result in excessive and sometimes uncontrolled cellular immune responses contributing to the severity of the disease [50]. In the case of SARS-CoV, it has been reported that a nonneutralizing mAb can disrupt the neutralizing activity of mAbs that inhibit infection in vitro [51, 52]. Overall, the results suggest that a cocktail of nmAbs binding to different epitopes may be a valid clinical approach [53].

The cocktail strategy may be especially relevant in the case of HIV where cytotoxic T lymphocytes and neutralizing Abs have long been known to select for immune escape mutations during the course of infection [54–57]. In addition, inactivation of bnAbs by non-nAbs has been reported [58–61]. This antagonism has been proposed to be due to steric hindrance [62]. In contrast, the observation of additive reactivity involving non-nmAbs and nmAbs suggests that multi-mAb combinations can support HIV inactivation irrespective of the individual mAb neutralizing potency [59]. In all probability, however, a cocktail approach to passive immunotherapy for HIV will need to involve highly crossneutralizing mAbs [63, 64] whose affinity and epitope locations can overcome the inhibitory effects of interfering non-nAbs.

### 3. Evasion Resulting from “Original Antigenic Sin”

The human immune system has evolved to respond very quickly and effectively to infectious challenges long after the primary infection has been resolved [65–68]. This immune memory is essentially a quick response capability that avoids the much slower process of the original immune reaction that ultimately gives rise to affinity maturation and an antibody repertoire. With memory, the antibody repertoire can be brought to bear in a matter of days, rather than weeks and months [65–68]. Whereas this rapid response can be essential to preventing repeated infections, it does however have some drawbacks that have provided the opportunity for certain viruses to continually establish successful infections. This susceptibility has to do with the characteristics of the initial immune response and the subsequent inability of the memory response to adequately broaden the repertoire of antibodies in the face of an infection by a similar or mutated strain. In essence, the diversity of a secondary immune response can be compromised by the dominance of the original immune response [69–71].

The first description of this phenomenon was published 60 years ago and was referred to as “original antigenic sin” (OAS) [72]. After an influenza virus infection, antibody produced after re-infection or vaccination with a related strain of virus is apparently still directed against the first strain that resulted in an immune response [73]. In other words, there was a recall of the first influenza virus experienced. This phenomenon, in which the immune system commits itself to the viral variant initially present and continues to make antibodies against the image of this virus even when contemporaneous virus has effectively shed this image, has been observed after infection by a number of viruses [36, 37, 74]. What stops the immune system from continually producing high-affinity neutralizing antibodies against emergent viral variants is not entirely clear.

One potential consequence of OAS is simply a lack of an adequate immune response to mutated virus. In addition, OAS presents a risk of the elicitation of Abs that could potentially enhance disease severity by enhancing viral infection. A prime example where this mechanism has been invoked is dengue virus. In the case of dengue, Abs derived from an initial immune response may act as agents that exacerbate disease by increasing the cellular uptake of viruses, resulting in higher viremia, a phenomenon termed antibody-dependent enhancement (ADE) [38]. While ADE has been the leading theory to explain the observation of increased risk of severe disease upon a secondary infection from a heterologous serotype, recent studies in humans have called into question ADE as the principal mechanism of increased disease risk [39, 75, 76]. Additionally, modifications to antibody Fc regions that disrupt antibody interaction with Fcy receptors have been shown to be effective strategies in preventing ADE-mediated lethal disease in a mouse model [77].

In spite of the apparent drawbacks of OAS, it has been shown that individuals can mount immune responses to an HIV infection that have all the hallmarks of an OAS response and nonetheless manage to generate bnAbs that coevolve with the mutating virus. A recent study followed this evolution in a single infected individual over a three year period [78]. In spite of the propensity for matured bnAbs to maintain neutralizing activity against the founder virus, potential viral escape mutations in the vicinity of the bnAb epitope were nonetheless neutralized due to bnAbs gaining neutralization breadth during affinity maturation.
4. Repertoire Freeze and Anti-Idiotypes

One explanation for OAS is that early induction of Ag-specific B cells and consequent free Abs are able to recognize viral escape mutants with sufficient affinity to successfully compete for viral antigens and minimize the effectiveness of naïve B cells encountering the viral escape [79]. Since these previously activated B cells and antigen-specific Abs are far more abundant than the naïve B cells, they can be selected to undergo somatic hypermutation and affinity maturation that, in some cases, can drive viral escape. The benefit of this phenomenon has been proposed to reside in an adaptive immune response that limits ineffective or even pathological antibodies along a narrow idiotypic axis, hence conserving idiotypic space for functional antibody responses [74].

It has been observed that those Abs derived from early infection very often carry a common idiotype, termed 1F7, that has been proposed as a potential target for therapeutic anti-idiotypic suppression [74, 79]. Whereas suppression of the 1F7 idiotype can allow for a higher titre of Abs capable of neutralizing the autologous contemporaneous viruses, some evidence suggests that bnAbs can develop within the 1F7 repertoire. It has been suggested that the continual selection of the 1F7-idiotype Abs may in fact drive the V region mutations that are the hallmark of HIV bnMAbs. Six well-characterized bnMAbs (b12, VRC01, 2F5, 4E10, 2G12, and Z13e1), and perhaps others, all express the 1F7 idiotype. In addition, the 1F7 idiotype has been found in Abs derived from other chronic infections such as HCV and SIV [74].

Some potential methods for avoiding OAS have been described [37]. These include masking gp120 epitopes [80, 81], using cytokines [82], and suppressing dominant B and T cell clones [80, 83].

5. Broadly Neutralizing Antibodies

The importance of conserved epitopes that are crucial to viral infection or propagation cannot be overstated. As targets of an immune response, conserved epitopes are the foundation of an antibody repertoire containing broadly neutralizing Abs. This is true for the immune response to variety of viruses. The immune response to influenza, for example, has provided insights into the difficulty of devising effective vaccine strategies [84]. This is because in influenza, as in other viruses, the best bnMAb candidates for use in therapy and prophylaxis are not directed against the major antigenic sites. Anti-influenza mAbs with broad-range neutralization activity against highly divergent isolates are generally able to interfere with the viral fusion process in the endosome vesicle by targeting conserved epitopes at that site. These bnMAbs are poorly induced by infection or vaccination as is the case with HIV and other viral infections. The bnMAbs against influenza and other viruses have been isolated by phage display techniques [41, 85, 86] or directly from human peripheral B cells [20, 44, 87].

Although a robust initial immune response to HIV infection is a hallmark of the disease, only about 20% of infected individuals mount an immune response that contains bnAbs. In addition, neutralizing immune responses rarely contain neutralizing antibodies against all the HIV clades. Broadly neutralizing anti-HIV mAbs are rare but there has been impressive recent progress, utilizing new mAb discovery technologies that have produced a variety of bnMAbs (Table 1) [87–94]. To date, there are approximately 50 bnMAbs that represent an essential arsenal of anti-infectious agents against HIV.

The hope that a single bnMAb will ultimately be found that will not readily select for escape mutations has persisted since the beginning of HIV antibody discovery [95]. The proposition that infectious diseases including HIV can be managed by the use of a cocktail of mAbs was suggested over ten years ago [96]. Clearly, for HIV, a cocktail of bnMAbs would stand a better chance of avoiding selection and providing protection and therapy [3]. The remainder of this paper will focus on HIV and the use of the broadly neutralizing anti-HIV mAbs that have been developed to date.

6. The Effectiveness of Multi-mAb Therapy

Progress towards establishing the effectiveness of a multi-mAb approach compared to single-mAb strategies has recently been reported [97, 98]. In one report [97], in order to evaluate the therapeutic potential of multiple broadly neutralizing antibodies on established HIV-1 infection, groups of humanized mice were infected with CCR5-tropic HIV-1 isolates (HIV-1Δ413). Humanized mice were used in order to minimize production of anti-human antibodies.

Mice were first treated using antibody monotherapy that evaluated five different broadly neutralizing antibodies. These antibodies were selected based on their neutralizing activity as well as the breadth of clades that could effectively be neutralized in vitro. In addition, each mAb targeted different epitopes. The serum half-lives of these mAbs ranged up to 6.3 days. In general, using monotherapy, viremia rebounded after 14–16 days with the concomitant appearance of gp120 mutants that allowed viral escape from mAb selection. Monotherapy therefore selected for viral escapes by mutation of antibody-targeted epitopes. The ability of a trimix and a penta-mix of bnMAbs to alter the course of infection was then evaluated. In contrast to monotherapy and the trimix, all of the pentamix-treated mice remained below baseline viral loads during the entire treatment course. Prolonged control of the infection was observed with the pentamix primarily due to the long serum half-life of the injected antibodies [99]. The efficacy of these antibody-based drugs may be further enhanced with modifications that extend half-life several folds [100].

Similar experiments in humanized mice and humans where multiple mAbs were evaluated for therapeutic efficacy against established infections did not reveal a significant benefit to the combination bnMAb approach [101–103]. In those experiments, the broadly neutralizing antibodies (b12,
Table 1: Broadly neutralizing monoclonal antibodies (bnMAbs) against HIV.

| Epitope | bnMAb | Discovery method | Median or range of IC_{50} values (μg mL^{-1}) | References |
|---------|--------|-----------------|---------------------------------------------|------------|
| MPER\(^1\) | 2F5 | EBV tfm\(^2\) | 3.8–7.8 [132] | [133] |
| | 4E10 | EBV tfm\(^2\) | 3.4 [134] | [88] |
| | 10E8, 7H6 | Neutralization assays\(^6\) | 0.3–1.5 [135] | [135] |
| | Z13e1 | Phage display | — | [57] |
| V1V2\(^3\) | PG9 | Neutralization assays\(^6\) | 0.1–9.4 [134] | [89] |
| | PG16 | Neutralization assays\(^6\) | 0.1–7.6 [136] | [89] |
| | CH01–04 | Neutralization assays | 0.02–4.9 (CH04) [137] | [137] |
| | PGT141–145 | Neutralization assays\(^6\) | 0.2–2.1 [134] | [134] |
| V3\(^4\) | 2G12 | EBV tfm\(^2\) | 2.4 [a] | [91] |
| | PGT121–123 | Neutralization assays\(^6\) | 0.03–0.05 [134] | [134] |
| | PGT125–131 | Neutralization assays\(^6\) | 0.02–0.5 [134] | [134] |
| | PGT135–137 | Neutralization assays\(^6\) | 0.2–7.8 [134] | [134] |
| | HGN194 | B cell immort\(^{10}\) | 0.1–3.7 [138] | [138] |
| | b12 | Phage display | 2.8 [134] | [92] |
| | HJ16 | B cell immort\(^{10}\) | 0.01–9.8 [138] | [138] |
| | VRC01–03 | RSC\(^7\) | 0.3 (VRC01 [134]) | [139] |
| | NIH44–46 | gp120, 140 probes\(^8\) | 0.06–1.9 [140, 141] | [140] |
| | 3BNC55, 60, 62, 117 | gp120, 140 probes\(^8\) | 0.01–1.4 (BNC117 [141]) | [140] |
| | 12A12, 21, 30 | gp120, 140 probes\(^8\) | 0.08–2.6 (12A12 [141]) | [140] |
| | VRC-PGV04, 4b | RSC\(^7\), pyrosequencing\(^9\) | 0.2 (PGV04 [134]) | [139] |
| | 8ANC37, 131, 134 | gp120, 140 probes\(^8\) | 0.06–6.3 (131 [141]) | [140] |
| | 1B2530 | gp120, 140 probes\(^8\) | 0.06–9.8 [141] | [140] |
| | 1NC3, 7, 9 | gp120, 140 probes\(^8\) | 0.02–1.2 (INC9[141]) | [140] |

1 Membrane-proximal external region of gp41.
2 EBV transformation of B cells.
3 V1V2 site on gp120.
4 Glycan V3 site on gp120.
5 CD4 binding site on gp120.
6 Neutralization assays of B cells from infected donors.
7 Resurfaced stabilized core 3 probe.
8 Somatic mutation primers, gp120 and gp140 probes.
9 454 pyrosequencing to characterize additional VRC01-like antibodies from HIV-1—infected individuals.
10 Efficient B cell immortalization and high throughput screening.

2G12, and 2F5 in mice; 2G12, 2F5, and 4E10 in humans) were less potent than VRC01 or the bnMAbs used in the Klein et. al. study [97]. This difference in potency as well as the inclusion of two additional mAbs to make a penta-mix may account for the different results.

The multi-mAb approach is similar to the combination therapies involving antiretroviral, antimicrobial, and anti-cancer agents since circumventing the selective pressure necessarily involves the simultaneous appearance of multiple mutations. Antibody therapy for HIV also offers the advantage of being able to specifically neutralize the virus, and can recruit other components of the immune system resulting in viral clearance from infected cells by eliciting effector functions [104]. Moreover, immune complexes from bnMAbs may augment native immunity and have far longer half-lives than antiretroviral drugs [105].

7. Multi-mAb Prevention of Transmission

A multi-mAb microbicide has demonstrated 100% efficacy in a humanized mouse model [106]. Broadly neutralizing HIV antibodies 2F5, 2G12, and 4E10 manufactured in mammalian cells and combined as MabGel have completed early clinical trials as a vaginal microbicide [107]. A Nicotiana-manufactured (see Section 9 below) multi-mAb consisting of VRC01-N, 10E8-N, and HSV8-N as an HSV/HIV microbicide is currently in development (Mapp Biopharmaceutical, 2013). Nicotiana-manufactured 2G12 mAb that was vaginally delivered has completed a small clinical trial; no product-related adverse events were reported (Julian Ma, personal communication).

Since intracellular virus would be better protected than free virus from adverse effects of antiviral factors in the
genital environment such as antiviral antibodies [108], and cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies [109], anti-cell mAbs [110, 111] will be an important component of a multi-mAb microbicide.

8. Regulatory Challenges of Multi-mAb Therapeutics

The regulatory and manufacturing challenges of a multi-mAb strategy have until recently been assumed to be nearly insurmountable. However both the regulatory and manufacturing procedures have been shown to be amenable to straightforward approaches involving FDA guidance and technological advances that have allowed for reproducible batch-to-batch potency as well as genetic stability and consistency [112]. A Phase 1 clinical trial has been performed with a three-mAb cocktail for botulinum toxin being developed by Xoma [113], and Phase 2 trials have been performed by Symphogen involving a 25-mAb and a two-mAb cocktail [114] and by Crucell (two-mAb rabies cocktail [115]).

In one recent report [112], product-specific methods addressing the polyclonality of a multi-mAb product were focused at the genetic level using a T-RFLP methodology, as well as at the protein level using CEIX- and MS-based methodologies to verify the consistency of manufactured batches. At the level of antigen reactivity, methods have been established to verify the potency of each antibody contained in each batch of the product. In December 2010, FDA published a draft Guidance for Industry entitled “Co-development of Two or More Unmarketed Investigational Drugs for use in Combination” (http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm). The recommendations in this, and an earlier draft guidance (FDA Points to Consider, February 28, 1997), may direct the development of recombinant antibody mixtures for multidisease products (e.g., HSV/HIV microbicides). New and cost-efficient cell banking and manufacturing concepts for multi-mAb products have been described [112, 115–121], and it has been demonstrated that a complex mAb composition containing 25 antibodies can be manufactured in a highly consistent manner in a scaled-up production process. This single-batch manufacturing concept represents a relatively simple approach to the production of complex mixtures of antibodies with an integrated high flexibility with respect to number of antibodies and design of composition.

9. Alternative Production Systems

Given the enormity of the HIV problem as well as the cost sensitivity inherent in the economic environments where HIV therapies are most urgently needed, alternatives to the mammalian cell culture technology might be appropriate. In the past, cost of production for life-threatening antibody-based drugs has not been a significant factor in determining the price of any particular drug [122]. In the case of HIV however the shear size of the unmet need may be beyond the current worldwide manufacturing capability of animal-cell-based production [122].

The cell culture system reported by Frandsen et al. [112] employed a recombination target site for integration of each individual mAb into the same genomic site thereby minimizing genomic position effects caused by the expression cassettes [123]. Each of these mammalian production cell lines is expected to be similar with regard to growth and production characteristics. Other production systems however obviate the need for uniform genetic integration events since no genomic integration is involved in generating the antibody producing cells. For example, using a transient plant system, expression of each mAb can result from the infection of plant cells by Agrobacterium tumefaciens [124]. This infection is performed after introducing several provectors into the Agrobacterium that can deliver the viral components and the foreign genes to plant cells. In this sense, Agrobacterium is the vehicle for primary infection and systemic movement in the plant, whereas the ultimately recombined, functional viral replicon provides cell-to-cell spread, amplification, and high expression. None of the provectors contain plant-selectable markers (e.g., kanamycin resistance), and they are not selected for genome integration and expression (a process that can consume years). Instead, the Agrobacterium-delivered provectors are engineered with specific recombinase sites that, when codelivered into the cell with their counterpart enzyme (phage C31 integrase), recombine efficiently in planta, forming the completed viral replicon. The mixing and codelivery of multiple Agrobacterium-based vectors, each containing a separate component of the viral replicon, is a fast and efficient method for expressing a wide range of proteins combining different elements. The combinatorial and iterative nature of antibody research is well matched to such an approach [124].

Unlike traditional transgenic plant production of mAbs which requires from months to years for scale-up (Table 2), the transient expression technology has proved not only versatile, but capable of rapid, high-yielding production of a variety of proteins [125]. Its ability to rapidly produce gram quantities of mAb within 10 days (from vector delivery to purified mAb) is exceptional in biopharmaceutical manufacturing. Dozens of mAbs to multiple pathogens have been produced in this fashion, and to date, all have been similar to those produced in mammalian cell culture when analyzed by a variety of in vitro and in vivo assays. In economic terms, the costs of manufacturing of mAbs for preclinical development using traditional mammalian cell culture (e.g., CHO or NS0) can be cost-prohibitive—cGMP—production of a mAb from CHO or NS0 as a contract manufacturer would cost a minimum of $5 M [122]. In contrast, production in the plant transient system under GMP has been estimated to require approximately one-sixth of that cost. It is also anticipated that significant cost-savings in the final commercial product will be realized where it is estimated that the drug substance at commercial scale will cost less than $50/g [126].

Glycosylation has historically been the only practical difference between mAbs produced in mammalian cell culture and in plant tissue [127]. Because of the potential for plant glycans to affect pharmacokinetics as well as immunogenicity
in humans, a transgenic *Nicotiana benthamiana* line with xylosyltransferase and fucosyltransferase activity effectively knockedout has been frequently used. The resulting glycans in the double-knockout are more homogeneous than current FDA-approved mAbs produced in mammalian cell culture. The 2G12 mAb (Table 1), when produced in the double-knockout plants to yield glycans without xylose or fucose, showed significantly enhanced binding to FcγRIIA and mediated higher antiviral activity [128]. It is noteworthy that although non-fucosylated mAbs are rare in CHO- and NS0-derived mAb products in comparison to the plant-produced mAb, a large fraction (~30%) of human serum IgG is non-fucosylated [129]. It is particularly relevant for *in vivo* studies that plant-derived mAbs have serum pharmacokinetics identical to those of mAbs produced in mammalian cell culture [130].

**10. Summary**

Viruses can escape the mammalian immune system by a variety of methods. The evasion methods that derive directly from the characteristic of our immune response include interfering non-nAbs, antibody-dependent enhancement of infection, and an attenuation of the immune response resulting in a limited diversity of Abs to mutated virus. There is a compelling rationale for multi-mAb products that can serve as both preventive and therapeutic drugs for HIV in particular and potentially for a variety of other infections that have proven to be recalcitrant to vaccine development. The availability of numerous broadly neutralizing mAbs for HIV provides the impetus for determining the most appropriate mAb combinations. In the future, multi-Ab candidates for HIV (and other viruses) may use a transformative strategy of epitope delineation based on neutralization fingerprints for screening sera or characterizing antibody specificities induced upon infection or vaccination [131]. In addition, new scalable production systems as well as a favorable regulatory environment may enable multi-mAb products for infectious diseases to be commercialized.

**References**

[1] B. D. Walker and D. R. Burton, “Toward an AIDS vaccine,” *Science*, vol. 320, no. 5877, pp. 760–764, 2008.

[2] M. Heckler, U.S. Health Secretary, news conference April 23, 1984.

[3] M. Nicasio, G. Sautto, N. Clementi et al., “Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?” *Viruses*, vol. 4, no. 9, pp. 1731–1752, 2012.

[4] D. H. Barouch, “Challenges in the development of an HIV-1 vaccine,” *Nature*, vol. 455, pp. 613–619, 2008.

[5] G. B. Karlsson Hedestam, R. A. M. Fouchier, S. Phogat, D. R. Burton, J. Sodroski, and R. T. Wyatt, “The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus,” *Nature Reviews Microbiology*, vol. 6, no. 2, pp. 143–155, 2008.

[6] H. L. Ploegh, “Viral strategies of immune evasion,” *Science*, vol. 280, no. 5361, pp. 248–253, 1998.

[7] B. T. Seet, J. B. Johnston, C. R. Brunetti et al., “Poxviruses and immune evasion,” *Annual Review of Immunology*, vol. 21, pp. 377–423, 2003.

[8] M. T. M. Vossen, E. M. Westerhout, C. Söderberg-Nauclér, and E. J. H. J. Wiertz, “Viral immune evasion: a masterpiece of evolution,” *Immunogenetics*, vol. 54, no. 8, pp. 527–542, 2002.

[9] D. R. Taylor, “Hepatitis C virus: evasion of the interferon-induced antiviral response,” *Journal of Molecular Medicine*, vol. 78, no. 4, pp. 182–190, 2000.

[10] J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial translocation is a cause of systemic immune activation in chronic HIV infection,” *Nature Medicine*, vol. 12, no. 12, pp. 1365–1371, 2006.

[11] S. Le Gall, L. Erdtmann, S. Benichou et al., “Nef interacts with the μ subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules,” *Immunity*, vol. 8, no. 4, pp. 483–495, 1998.

[12] O. O. Yang, P. T. Nguyen, S. A. Kalams et al., “Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes,” *Journal of Virology*, vol. 76, no. 4, pp. 1626–1631, 2002.

[13] R. Wyatt and J. Sodroski, “The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens,” *Science*, vol. 280, no. 5371, pp. 1884–1888, 1998.

[14] T. W. Chun, L. Carruth, D. Finzi et al., “Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection,” *Nature*, vol. 387, no. 6629, pp. 183–188, 1997.

[15] B. Korber, B. Gaschen, K. Yusim, R. Thakallapally, C. Kesmir, and V. Detours, “Evolutionary and immunological implications of contemporary HIV-1 variation,” *British Medical Bulletin*, vol. 58, pp. 19–42, 2001.

[16] S. Ubol and S. B. Halstead, “How innate immune mechanisms contribute to antibody-enhanced viral infections,” *Clinical and Vaccine Immunology*, vol. 17, no. 12, pp. 1829–1835, 2010.

[17] T. J. Broering, K. A. Garrity, N. K. Boatright et al., “Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus,” *Journal of Virology*, vol. 83, no. 23, pp. 12473–12482, 2009.

[18] T. Krey, J. D’Alayer, C. M. Kikuti et al., “The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule,” *PLoS Pathogens*, vol. 6, no. 2, Article ID e1000762, 2010.

[19] M. Perotti, N. Mancini, R. A. Diotti et al., “Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein,” *Journal of Virology*, vol. 82, no. 2, pp. 1047–1052, 2008.

[20] R. Burioni, F. Canducci, N. Mancini et al., “Molecular cloning of the first human monoclonal antibodies neutralizing with high potency Swine-origin Influenza A pandemic virus (S-OIV),” *New Microbiologica*, vol. 32, no. 4, pp. 319–324, 2009.
[21] Y. Wang, Z. Y. Keck, A. Saha et al., “Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus,” Journal of Biological Chemistry, vol. 286, pp. 44218–44233, 2011.

[22] M. C. Sabo, V. C. Luca, J. Prentoe et al., “Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step,” Journal of Virology, vol. 85, pp. 7005–7019, 2011.

[23] R. Burioni, N. Mancini, F. Canducci et al., “Humoral immune response against hepatitis C virus,” Journal of Biological Regulators and Homeostatic Agents, vol. 17, no. 2, pp. 125–127, 2003.

[24] F. Bugli, N. Mancini, C. Y. Kang et al., “Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries,” Journal of Virology, vol. 75, no. 20, pp. 9986–9990, 2001.

[25] E. Giang, M. Dorner, J. C. Prentoe et al., “Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, pp. 6205–6210, 2012.

[26] Z. Y. Keck, J. Xia, and Y. Wang, “Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate,” PLOS Pathogens, vol. 8, Article ID e1002653, 2012.

[27] R. Burioni, F. Bugli, N. Mancini et al., “Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs,” Virology, vol. 288, no. 1, pp. 29–35, 2001.

[28] P. Zhang, L. Zhong, E. B. Struble et al., “Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 18, pp. 7537–7541, 2009.

[29] R. Burioni, Y. Matsuura, N. Mancini et al., “Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype,” Journal of Virology, vol. 76, no. 22, pp. 11775–11779, 2002.

[30] N. Mancini, F. Canducci, S. Carletti et al., “Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies,” Journal of Biological Regulators and Homeostatic Agents, vol. 17, no. 2, pp. 183–187, 2003.

[31] R. Burioni, N. Mancini, S. Carletti et al., “Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection,” Virology, vol. 327, no. 2, pp. 242–248, 2004.

[32] N. Mancini, S. Carletti, M. Perotti et al., “Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment,” Journal of Medical Virology, vol. 78, no. 10, pp. 1304–1311, 2006.

[33] C. Di Lorenzo, A. G. Angus, and A. H. Patel, “Hepatitis C virus evasion mechanisms from neutralizing antibodies,” Viruses, vol. 3, pp. 2280–2300, 2011.

[34] Y. S. El Abd, A. A. Tabll, N. G. El Din et al., “Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2,” Virology Journal, vol. 8, article 391, 2011.

[35] G. Sautto, N. Mancini, R. A. Diotti, L. Solforosi, M. Clementi, and R. Burioni, “Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference,” Antiviral Research, vol. 96, pp. 82–89, 2012.

[36] A. L. Rothman, “Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms,” Nature Reviews Immunology, vol. 11, no. 8, pp. 532–543, 2011.

[37] S. Muller, “Avoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development,” International Reviews of Immunology, vol. 23, no. 5-6, pp. 423–436, 2004.

[38] B. R. Murphy and S. S. Whitehead, “Humoral immune response against dengue virus and prospects for a vaccine,” Annual Review of Immunology, vol. 29, pp. 587–619, 2011.

[39] A. Sabchareon, D. Wallace, C. Sirivichayakul et al., “Protective efficacy of the recombinant, live-attenuated CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial,” Lancet, vol. 380, no. 9583, pp. 1599–1567, 2012.

[40] N. Clementi, D. De Marco, N. Mancini et al., “A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes,” PLoS ONE, vol. 6, Article ID e28001, 2011.

[41] J. Sui, W. C. Hwang, S. Perez et al., “Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses,” Nature Structural and Molecular Biology, vol. 16, no. 3, pp. 265–273, 2009.

[42] M. Knossow, M. Gaudier, A. Douglas et al., “Mechanism of neutralization of influenza virus infectivity by antibodies,” Virology, vol. 302, no. 2, pp. 294–298, 2002.

[43] D. De Marco, N. Clementi, and N. Mancini, “A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses,” PLoS ONE, vol. 7, Article ID e34415, 2012.

[44] R. Burioni, F. Canducci, N. Mancini et al., “Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV),” Virology, vol. 399, no. 1, pp. 144–152, 2010.

[45] K. K. To, A. J. Zhang, I. F. Hung et al., “High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza,” Clinical and Vaccine Immunology, vol. 19, pp. 1012–1018, 2012.

[46] M. Elhfenawi, O. Alaidi, N. Mohamed et al., “Identification of novel conserved functional motifs across most Influenza A viral strains,” Virology Journal, vol. 8, article 44, 2011.

[47] L. Solforosi, N. Mancini, F. Canducci et al., “A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments,” New Microbiologica, vol. 35, pp. 289–294, 2012.

[48] W. Ndifon, N. S. Wingreen, and S. A. Levin, “Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 21, pp. 8701–8706, 2009.

[49] Z. Zhou, P. Post, R. Chubet et al., “A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice,” Vaccine, vol. 24, no. 17, pp. 3624–3631, 2006.
[50] S. Perlman and A. A. Dandekar, "Immunopathogenesis of coronavirus infections: implications for SARS," *Nature Reviews Immunology*, vol. 5, no. 12, pp. 917–927, 2005.

[51] L. Zhong, L. Haynes, E. B. Struble, A. Tamin, M. L. Virata-Theimer, and P. Zhang, "Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein," *Biochemical and Biophysical Research Communications*, vol. 390, no. 3, pp. 1056–1060, 2009.

[52] R. A. Tripp, L. M. Haynes, D. Moore et al., "Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and e viral proteins," *Journal of Virological Methods*, vol. 128, no. 1–2, pp. 21–28, 2005.

[53] M. M. Coughlin and B. S. Prabhakar, "Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential," *Reviews in Medical Virology*, vol. 22, pp. 2–17, 2012.

[54] D. D. Richman, T. Win, S.J. Little, and C.J. Petropoulos, "Rapid evolution of the neutralizing antibody response to HIV type 1 infection," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, pp. 4144–4149, 2003.

[55] R. E. Phillips, S. Rowland-Jones, D. F. Nixon et al., "Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition," *Nature*, vol. 354, no. 6355, pp. 453–459, 1991.

[56] F. Canducci, M. C. Marinozzi, M. Sampolo et al., "Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long-term non progressor (LTNP) subjects," *Retrovirology*, vol. 6, article 4, 2009.

[57] M. B. Zwick, M. Wang, P. Poignard et al., "Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies," *Journal of Virology*, vol. 75, no. 24, pp. 12198–12208, 2001.

[58] J. E. S. Hansen, A. M. Sorensen, S. Olofsson, E. Osinaga, and A. Roseto, "Combination effect on HIV infection in vitro of soluble CD4 and HIV-neutralizing antibodies," *Archives of Virology*, vol. 134, no. 1-2, pp. 179–184, 1994.

[59] F. Verrier, A. Nádas, M. K. Gorny, and S. Zolla-Pazner, "Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6," *Journal of Virology*, vol. 75, no. 19, pp. 9177–9186, 2001.

[60] W. Yuan, X. Li, M. Kasterka, M. K. Gorny, S. Zolla-Pazner, and J. Sodroski, "Oligomer-specific conformations of the Human Immunodeficiency Virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies," *AIDS Research and Human Retroviruses*, vol. 25, no. 3, pp. 319–328, 2009.

[61] S. M. Dennison, K. Anasti, R. M. Scearce et al., "Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens," *Journal of Virology*, vol. 85, no. 3, pp. 1340–1347, 2011.

[62] M. K. Gorny and S. Zolla-Pazner, "Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41," *Journal of Virology*, vol. 74, no. 13, pp. 6186–6192, 2000.

[63] N. Clementi, N. Mancini, L. Solfosori, M. Castelli, M. Clementi, and R. Burioni, "Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens," *International Journal of Molecular Sciences*, vol. 13, pp. 8273–8292, 2012.

[64] N. Mancini, M. Clementi, and R. Burioni, "Natalizumab-associated progressive multifocal leukoencephalopathy," *New England Journal of Medicine*, vol. 367, pp. 871–872, 2012.

[65] K. Kedzierska, S. A. Valkenburg, P. C. Doherty, M. P. Davenport, and V. Venturi, "Use it or lose it: establishment and persistence of T cell memory," *Frontiers in Immunology*, vol. 3, article 357, 2012.

[66] M. Shapiro-Shelef and K. Calame, "Regulation of plasma-cell antibody responses," *Nature Reviews Immunology*, vol. 5, pp. 230–242, 2005.

[67] L. J. McHeyzer-Williams and M. G. McHeyzer-Williams, "Antigen-specific memory B cell development," *Annual Review of Immunology*, vol. 23, pp. 487–513, 2005.

[68] J. Jacob, G. Kelsoe, K. Rajewsky, and U. Weiss, "Intraclonal generation of antibody mutants in germinal centres," *Nature*, vol. 354, no. 6352, pp. 389–392, 1991.

[69] R. G. Webster, "Original antigenic sin in ferrets: the response to sequential infections with influenza viruses," *Journal of Virology*, vol. 97, no. 2, pp. 177–183, 1966.

[70] F. M. Davenport, A. V. Hennessy, and T. Francis Jr., "Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus," *The Journal of Experimental Medicine*, vol. 98, no. 6, pp. 641–656, 1953.

[71] K. E. Jensen, F. M. Davenport, A. V. Hennessy, and T. Francis Jr., "Characterization of influenza antibodies by serum absorption," *The Journal of Experimental Medicine*, vol. 104, no. 2, pp. 199–209, 1956.

[72] T. Francis Jr., "Influenza: the new acquaintance," *Annals of Internal Medicine*, vol. 39, no. 2, pp. 203–221, 1953.

[73] T. Francis Jr., F. M. Davenport, and A. V. Hennessy, "A serologic recapitulation of human infection with different strains of influenza virus," *Transactions of the Association of American Physicians*, vol. 66, pp. 231–239, 1953.

[74] M. D. Grant, "Antibody convergence along a common idiotypic axis in immunodeficiency virus and hepatitis C virus infections," *Journal of Medical Virology*, vol. 66, pp. 13–21, 2002.

[75] K. Laoprasopawatana, D. H. Librarty, T. P. Endy et al., "Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection," *Journal of Infectious Diseases*, vol. 192, no. 3, pp. 510–519, 2005.

[76] T. P. Endy, A. Nisalak, S. Chunsuttiwat et al., "Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand," *Journal of Infectious Diseases*, vol. 189, no. 6, pp. 990–1000, 2004.

[77] M. Beltramello, K. L. Williams, C. P. Simmons et al., "The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity," *Cell Host and Microbe*, vol. 8, no. 3, pp. 271–283, 2010.

[78] H. H. Liao, R. Lynch, T. Zhou et al., "Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus," *Nature*, vol. 496, pp. 469–476, 2013.

[79] M. S. Parsons, D. Rouleau, J. P. Routy, R. Leblanc, M. D. Grant, and N. F. Bernard, "Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen IF7-idiotypic repertoire," *AIDS*, vol. 25, no. 10, pp. 1259–1264, 2011.
[80] H. Kohler, S. Muller, and P. L. Nara, “Deceptive imprinting in the immune response against HIV-1,” *Immunology Today*, vol. 15, no. 10, pp. 475–478, 1994.

[81] P. L. Nara and R. Garrity, “Deceptive imprinting: a cosmopolitan strategy for complicating vaccination,” *Vaccine*, vol. 16, no. 19, pp. 1780–1787, 1998.

[82] J. Salk, P. A. Bretscher, P. L. Salk, M. Clerici, and G. M. Shearer, “A strategy for prophylactic vaccination against HIV,” *Science*, vol. 260, no. 5112, pp. 1270–1272, 1993.

[83] H. Wang, S. Muller, S. Zolla-Pazner, and H. Kohler, “Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity,” *European Journal of Immunology*, vol. 22, no. 7, pp. 1749–1755, 1992.

[84] N. Clementi, E. Criscuolo, M. Castelli, and M. Clementi, “Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis,” *New Microbiologica*, vol. 35, no. 4, pp. 399–406, 2012.

[85] A. K. Kashyap, J. Steel, A. F. Oner et al., “Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 16, pp. 5986–5991, 2008.

[86] M. Throsby, E. van den Brink, M. Jongeneelen et al., “Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells,” *PLoS ONE*, vol. 3, no. 12, Article ID e3942, 2008.

[87] D. Corti, J. Voss, S. J. Gamblin et al., “A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins,” *Science*, vol. 333, no. 6044, pp. 850–856, 2011.

[88] G. Stiegler, R. Kunert, M. Purtscher et al., “A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1,” *AIDS Research and Human Retroviruses*, vol. 17, no. 18, pp. 1757–1765, 2001.

[89] L. M. Walker, S. K. Phogat, P. Y. Chan-Hui et al., “Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target,” *Science*, vol. 326, pp. 285–289, 2010.

[90] L. Stamatatos, L. Morris, D. R. Burton, and J. R. Mascola, “Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?” *Nature Medicine*, vol. 15, pp. 866–870, 2009.

[91] A. Trkola, A. B. Pomailes, H. Yuan et al., “Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG,” *Journal of Virology*, vol. 69, no. 11, pp. 6609–6617, 1995.

[92] D. R. Burton, J. Pyati, R. Koduri et al., “Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody,” *Science*, vol. 266, pp. 1024–1027, 1994.

[93] P. D. Kwong and I. A. Wilson, “HIV-1 and influenza antibodies: seeing antigens in new ways,” *Nature Immunology*, vol. 10, no. 6, pp. 573–578, 2009.

[94] M. D. Simek, W. Rida, F. H. Priddy et al., “Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm,” *Journal of Virology*, vol. 83, no. 14, pp. 7337–7348, 2009.

[95] J. R. Mascola, M. G. Lewis, G. Stiegler et al., “Protection of macaques against pathogenic simian/humanimmunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies,” *Journal of Virology*, vol. 73, pp. 4009–4018, 1999.

[96] K. J. Whaley and L. Zeitlin, “Antibodies as mucosal protectants,” *Annales de l’Institut Pasteur/Actualites*, vol. 7, pp. 83–100, 2001.

[97] F. Klein, A. Halper-Stromberg, J. A. Horwitz et al., “HIV therapy by a combination of broadly neutralizing antibodies in humanized mice,” *Nature*, vol. 492, no. 7427, pp. 118–122, 2012.

[98] N. A. Doria-Rose, M. K. Louder, Z. Yang et al., “HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes,” *Journal of Virology*, vol. 86, no. 6, pp. 3393–3397, 2012.

[99] N. Mancini, L. Solforosi, N. Clementi, D. De Marco, M. Clementi, and R. Burioni, “A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza,” *Antiviral Research*, vol. 92, pp. 15–26, 2011.

[100] P. R. Hinton, J. M. Xiong, M. G. Johils, M. T. Tang, S. Keller, and N. Tsurushita, “An engineered human IgG1 antibody with longer serum half-life,” *Journal of Immunology*, vol. 176, no. 1, pp. 346–356, 2006.

[101] P. Poignard, R. Sabbe, G. R. Picchio et al., “Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo,” *Immunity*, vol. 10, no. 4, pp. 431–438, 1999.

[102] S. Mehandru, B. Vceral, T. Wrin et al., “Adjuvative passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection,” *Journal of Virology*, vol. 81, no. 20, pp. 11016–11031, 2007.

[103] A. Trkola, H. Kuster, P. Ruset et al., “Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies,” *Nature Medicine*, vol. 11, no. 6, pp. 615–622, 2005.

[104] F. Nimmerjahn and J. V. Ravetch, “Antibody-mediated modulation of immune responses,” *Immunological Reviews*, vol. 236, pp. 265–275, 2010.

[105] C. T. Ng, J. P. Jaworski, P. Jayaraman et al., “Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques,” *Nature Medicine*, vol. 16, no. 10, pp. 1117–1119, 2010.

[106] M. Veselinovic, C. P. Neff, L. R. Mulder, and R. Akkina, “Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model,” *Virology*, vol. 432, no. 2, pp. 505–510, 2012.

[107] G. Morris, S. Chindove, S. Woodhall et al., “A prospective randomized double blind placebo-controlled phase 1 pharmacokinetic and safety study of a vaginal microbicide gel containing three potent broadly neutralizing monoclonal antibodies (2F5, 2G12, 4E10)(MabGel),” *Microbicides*, Abstract LBI, 2010.

[108] D. J. Anderson, J. A. Politch, A. M. Nadolski, C. D. Blaskewicz, J. Pudney, and K. H. Mayer, “Targeting trojan horse leukocytes enabling HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 external region but not surface unit-directed broadly neutralizing antibodies,” *Immunology*, vol. 105, no. 16, pp. 5986–5991, 2012.

[109] I. A. Abela, L. Berlinger, M. Schanz et al., “Cell–cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies,” *PLOS Pathogens*, vol. 8, no. 4, Article ID e1002634, 2012.

[110] M. Sagar, H. Akiyama, B. Etemad, N. Ramirez, I. Freitas, and S. Gummulu, “Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 infection.”
trans-infection,” *Journal of Infectious Diseases*, vol. 205, no. 8, pp. 1248–1257, 2012.

[112] M. A. Moody, H. X. Liao, S. M. Alam et al., “Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines,” *Journal of Experimental Medicine*, vol. 207, no. 4, pp. 763–776, 2010.

[113] T. P. Frandsen, H. Naested, S. K. Rasmussen et al., “Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use,” *Biotechnology and Bioengineering*, vol. 108, no. 9, pp. 2171–2181, 2011.

[114] A. B. Tolstrup, T. P. Frandsen, and S. Bregenholt, “Development of target-specific recombinant human polyclonal antibodies in plants coinfected with noncompeting viral vectors,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 40, pp. 14701–14706, 2006.

[115] G. P. Pogue, F. Vojdani, K. E. Palmer et al., “Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems,” *Plant Biotechnology Journal*, vol. 8, no. 5, pp. 638–654, 2010.

[116] D. Bosch, A. Castilho, A. Loos, A. Schots, and H. Steinkellner, “N-Glycosylation of plant-produced recombinant proteins,” *Current Pharmaceutical Design*, 2013.

[117] D. N. Forthal, J. S. Gach, G. Landucci et al., “Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12,” *Journal of Immunology*, vol. 185, no. 11, pp. 6876–6882, 2010.

[118] J. N. Arnold, M. R. Wormald, R. B. Sim, P. M. Rudd, and R. A. Dwek, “The impact of glycosylation on the biological function and structure of human immunoglobulins,” *Annual Review of Immunology*, vol. 25, pp. 21–50, 2007.

[119] L. Zeitlin, O. Bohorov, N. Bohorova et al., “Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model,” *Monoclonal Antibodies*, vol. 5, no. 2, 2013.

[120] I. S. Georgiev, N. A. Doria-Rose, T. Zhou et al., “Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization,” *Science*, vol. 340, no. 6133, pp. 751–756, 2013.

[121] G. Zhang, H. Lu, Y. Lu, S. Jiang, and Y. H. Chen, “Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies,” *Immunobiology*, vol. 210, no. 9, pp. 639–645, 2005.

[122] T. Muster, R. Guinea, A. Trkola et al., “Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS,” *Journal of Virology*, vol. 68, no. 6, pp. 4031–4034, 1994.

[123] L. M. Walker, M. Huber, K. D. Doores et al., “Broad neutralization coverage of HIV by multiple highly potent antibodies,” *Nature*, vol. 477, no. 7365, pp. 466–470, 2011.

[124] J. Huang, G. Ofek, L. Laub et al., “Broad and potent neutralization of HIV-1 by a gp41-specific human antibody,” *Nature*, vol. 491, no. 7424, pp. 406–412, 2012.

[125] M. Braibant, E. Y. Gong, J. C. Plantier et al., “Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups,” *AIDS*, 2013.

[126] M. Bonsignori, K. K. Hwang, X. Chen et al., “Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors,” *Journal of Virology*, vol. 99, pp. 10009–10009, 2011.

[127] D. Corti, J. P. M. Langedijk, A. Hinz et al., “Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals,” *PLoS ONE*, vol. 5, no. 1, Article ID e8805, 2010.

[128] X. Wu, Z. Y. Yang, Y. Li et al., “Rational design of envelope body manufacture,” *Journal of Chromatography B*, vol. 848, no. 1, pp. 8–18, 2007.

[129] A. B. Tolstrup, T. P. Frandsen, and S. Bregenholt, “Development of target-specific recombinant human polyclonal antibodies in plants coinfected with noncompeting viral vectors,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 40, pp. 14645–14646, 2006.

[130] A. Giritich, S. Marillonnet, C. Engler et al., “Rapid high-yield expression of full-size IgG antibodies in plants coinfectcd with noncompeting viral vectors,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 40, pp. 14645–14646, 2006.

[131] F. Wibeck, S. K. Rasmussen, T. P. Frandsen et al., “Production of target-specific recombinant human polyclonal antibodies in mammalian cells,” *Biotechnology and Bioengineering*, vol. 94, no. 2, pp. 396–405, 2006.

[132] S. S. Farid, “Process economics of industrial monoclonal antibody manufacture,” *Journal of Chromatography B*, vol. 848, no. 1, pp. 8–18, 2007.

[133] J. Gao, S. Cha, R. Jonsson, J. Opalko, and A. B. Peck, “Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assay,” *Arthritis and Rheumatism*, vol. 50, no. 8, pp. 2626–2628, 2004.

[134] A. Hiatt and M. Pauly, “Monoclonal antibodies from plants: a new speed record,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 40, pp. 14645–14646, 2006.
[141] R. Diskin, J. F. Scheid, P. M. Marcovechio et al., “Increasing the potency and breadth of an HIV antibody by using structure-based rational design,” *Science*, vol. 334, no. 6060, pp. 1289–1293, 2011.